Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

YiChang HEC ChangJiang Pharmaceutical Co., Ltd.
宜昌東陽光長江藥業股份有限公司
(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 01558)

VOLUNTARY ANNOUNCEMENT
EMITASVIR PHOSPHATE CAPSULES APPROVED TO LAUNCH

This announcement is made by YiChang HEC ChangJiang Pharmaceutical Co., Ltd. (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis.

References are made to the announcements of the Company dated 19 August 2019 and 11 September 2019. The board of directors (the "**Board**") of the Company is pleased to announce that the Company's self-researched and developed product Emitasvir Phosphate Capsules (0.1g) (the "**Product**") have undergone the assessment and approval process and obtained approval for launch from the China National Medical Products Administration.

Name of the drug (Chinese)	磷酸依米他韋膠囊
Name of the drug (English)	Emitasvir Phosphate Capsules
Form	Capsules
Specification	0.1g
Registration category	Type 1 Chemical Drug
Handling number	CXHS1900030GUO
Drug approval number	Guoyaozhunzi (國藥准字) H20200015
Certificate number	2020S00879
Marketing authorization holder	YiChang HEC ChangJiang Pharmaceutical Co., Ltd.

Emitasvir Phosphate is an anti-hepatitis C oral direct-acting antiviral drug, non-structural protein ("**NS**") 5A inhibitor. The drug is effective in treating liver cirrhosis-free genotype 1 Hepatitis C patients with SVR12 (sustained virological response in 12 weeks) at 99.8%, while maintaining favourable safety and tolerance properties.

Emitasvir Phosphate Capsule is national Class 1 innovative new drug in China. According to data from IMS, the sales of anti-hepatitis C oral antiviral drug in China in 2019 was more than USD13 million (representing an increase of 75.3% as compared to 2018), possessing huge growth potential.

Upon approval for launch, the Product has become one of the major products of the Company in the field of anti-hepatitis C treatment. It has high clinical value and favourable market prospects. Moreover, it will be beneficial for the expansion of the Group's antiviral business and the Group's product portfolio will be further enriched and will provide patients with a wider choice of medication with high quality and fair price.

This announcement is made by the Company on a voluntary basis to keep investors informed of the latest business development of the Group, and contains no advertisement or intention regarding the use of any drug, surgical device, therapy or oral product.

On behalf of the Board
YiChang HEC ChangJiang Pharmaceutical Co., Ltd.
TANG Xinfa
Chairman

Hubei, the PRC

28 December 2020

As of the date of this announcement, the Board consists of Mr. JIANG Juncai, Mr. WANG Danjin, Mr. CHEN Yangui and Mr. LI Shuang as executive directors; Mr. TANG Xinfa and Mr. Eddy HUANG as non-executive directors; and Mr. TANG Jianxin, Mr. ZHAO Dayao, Ms. XIANG Ling and Mr. LI Xuechen as independent non-executive directors.